Overview

R (Bell and A) v Tavistock and Portman NHS Foundation Trust was a judicial review in England and Wales: a public-law challenge to the lawfulness of a public body's policy, not a claim for damages. Keira Bell (named "Quincy Bell" in the proceedings), a former patient of the Tavistock's Gender Identity Development Service (GIDS), and "Mrs A", the mother of an autistic teenage girl, argued that children and young people under 18 could not give valid consent to puberty blockers. On 1 December 2020 the High Court (sitting as a Divisional Court) said it was "highly unlikely" that a child aged 13 or under could consent, and doubtful that 14- and 15-year-olds could. On 17 September 2021 the Court of Appeal set that ruling aside, and in May 2022 the UK Supreme Court refused permission for a further appeal. As of October 2026 the case is closed. Bell lost in law, but the evidence aired in the case fed into the Cass Review (an independent review of NHS gender services for young people, led by paediatrician Hilary Cass; see below), the closure of GIDS and the UK's current restrictions on puberty blockers.

Background

Keira Bell

This account comes from Bell's witness statement as the High Court recorded it, and from her own public statements. She described "a highly traumatic childhood", gender non-conformity from the age of 4 or 5, disgust with her body, depression and anxiety, and online research into gender identity from 14 (High Court 2020, para 78). She was referred to GIDS at 15 and first seen there at 16. She was referred to University College London Hospitals (UCLH) in June 2013 and started puberty blockers after three appointments. She started testosterone at 17 and had a double mastectomy at 20 (paras 79–81). She stopped testosterone in January 2019 (para 83).

Her witness statement, quoted by the court, described the moment she realised the transition had not given her what she expected:

I started to just see a woman with a beard, which is what I was. I felt like a fraud and I began to feel more lost, isolated and confused than I did when I was pre-transition. — Keira Bell's witness statement, quoted in (High Court 2020, para 81)

Earlier doubts had been waved away by online forums where "the consensus was that most transsexual people have doubts and that that is a normal part of transitioning, so the doubts should be ignored" (para 80). In a 2021 essay she wrote that by the time she reached the clinic she "was adamant that I needed to transition," calling it "the kind of brash assertion that's typical of teenagers" (Bell 2021, Persuasion).

Mrs A

The second claimant was the mother of a 15-year-old girl with autism spectrum disorder (ASD) and a history of mental-health and behavioural problems. According to the judgment, the girl "is desperate to run away from all that made her female" (High Court 2020, para 89). Before the ruling Mrs A told the BBC: "My fear is - it's not that she transitions - it's that she gets it wrong" (BBC 2020).

The two courts described her position differently. The High Court said the daughter had not been referred to GIDS and, because her parents would not support treatment, would not currently meet the criteria for blockers, so Mrs A's interest was "largely theoretical" (para 89). The Court of Appeal said the child "has been referred to Tavistock, but has not yet had an appointment" (Court of Appeal 2021, para 4). News reports described her as on the waiting list.

The claims

The case was a challenge to GIDS's "continuing practice … to prescribe puberty-suppressing hormone blockers to children under the age of 18" (Court of Appeal 2021, para 4). The High Court summarised the claimants' case in three parts (High Court 2020, paras 7, 90–94):

• Incapacity. Under-18s are not competent to consent to puberty blockers, because blockers are, in practice, the first step to cross-sex hormones and their lifelong effects on fertility and sexual function.
• Misleading information. The information given to children was "misleading and insufficient". In particular, they argued, describing blockers as "fully reversible" understated both the unknowns and the likelihood of going on to cross-sex hormones.
• Article 8 / procedural safeguards. Without court oversight, children's rights under Article 8 of the European Convention on Human Rights were infringed. The relief sought was a declaration that prescribing blockers without a court order in the child's best interests was unlawful.

Counsel for the claimants, Jeremy Hyam QC (Queen's Counsel, a senior barrister), made clear what the claim did not argue. It did not question that gender dysphoria exists or that it can cause extreme distress, and it did not argue "that PBs should never be given to people under 18" (para 92; "PBs" is the judgment's abbreviation for puberty blockers). The Court of Appeal later noted that it was "no part of the claim" that the treatment was unlawful in itself (Court of Appeal 2021, para 3).

Defendants' position

The Tavistock and Portman NHS Foundation Trust, represented by Fenella Morris QC, was supported by the two hospital trusts that actually prescribed the drugs (UCLH and Leeds Teaching Hospitals), which intervened. They argued that:

• the consent process was "deeply Montgomery compliant" (meeting the informed-consent standard set by the UK Supreme Court in Montgomery v Lanarkshire Health Board, 2015), with many consultations and age-appropriate information, and that the "vast majority" of children referred were 15 or older (High Court 2020, para 98);
• blockers (stage 1) and cross-sex hormones (stage 2) are separate decisions with separate consent, so a child need only understand stage 1 (paras 56, 136);
• the primary purpose of blockers was to give "time to think" (para 52);
• once a child reached the endocrine clinic, the clinicians were facing a child in acute distress with "no alternative treatment options" (para 100).

They also filed evidence from young people who supported their treatment. "J", who started blockers at 12, said he wished they had been started earlier, "which would have prevented the need for breast surgery later" (para 86). "N" said blockers "may very well have saved my life" (para 88). After the High Court ruling the Trust said it was "disappointed" and that the outcome was "likely to cause anxiety for patients and their families" (BBC 2020).

On appeal the Tavistock argued, among eight grounds, that the court had misapplied Gillick (the 1985 House of Lords ruling that a child under 16 can consent to medical treatment if they have enough understanding and intelligence to fully grasp what is proposed, known as Gillick competence), wrongly called the treatment "experimental" and relied on untested expert evidence (Court of Appeal 2021, para 12). The sexual-health charity Brook, the trans charity Gendered Intelligence and the Endocrine Society (a professional body for hormone specialists) supported the appeal. The gender-critical group Transgender Trend intervened on the claimants' side.

The evidence before the court

The High Court said repeatedly that it was not deciding whether blockers were clinically beneficial. That was for the NHS and regulators (High Court 2020, paras 9, 74). But it did comment on gaps in the data that the Tavistock itself provided.

Missing data

• Age profile. The Trust had not collated the ages of children given blockers between 2011 and 2020. For 2019/20 it showed that 161 children were referred for blockers: 26 were aged 13 or under and 95 were under 16 (paras 27–29). The court found it "surprising that such data was not collated in previous years given the young age of the patient group, the experimental nature of the treatment and the profound impact that it has" (para 28).
• Autism. The court asked how many children referred for blockers had an ASD diagnosis. The Trust said the data was not available, and the court called this "lack of data analysis – and the apparent lack of investigation of this issue - surprising" (paras 34–35).
• Sex ratio and referrals. Referrals rose from 97 in 2009 to 2,519 in 2018. Natal females made up 76% of referrals in 2019, up from roughly half in 2011. "The defendant did not put forward any clinical explanation" for the change (paras 31–32). For more on this shift, see demographic shift in trans identification.
• Unpublished research. The UK's Early Intervention Study, begun in 2011, was still unpublished at the hearing. A 2014 summary noted "no overall improvement in mood or psychological wellbeing using standardized psychological measures" (paras 24, 73).

Progression from blockers to cross-sex hormones

The core of the High Court's reasoning was that blockers and cross-sex hormones are, in practice, one pathway. The Tavistock's own expert, Dr Annelou de Vries of Amsterdam, said that only 1.9% of adolescents who started puberty suppression stopped without going on to cross-sex hormones (para 57). The Tavistock said it held no data on that proportion for its own patients (para 58). A random sample of 312 of 1,648 files of patients discharged in 2019–20 found that 49 had been seen by endocrinology and, of those, 27 (55%) had been approved for or had started cross-sex hormones while still at GIDS.

From this the court concluded:

The evidence shows that the vast majority of children who take PBs move on to take cross-sex hormones, that Stages 1 and 2 are two stages of one clinical pathway and once on that pathway it is extremely rare for a child to get off it. — (High Court 2020, para 136)

The Early Intervention Study was published in February 2021, after the High Court hearing. It reported that at the end of the study 43 of 44 participants (98%) chose to start cross-sex hormones, and found no change in psychological-function scores (Carmichael et al. 2021).

The Court of Appeal was more cautious. It read the Tavistock's evidence as showing that "more than half" went on to cross-sex hormones, and noted the argument that high progression might reflect patient selection rather than blockers causing persistence (Court of Appeal 2021, para 64). It also pointed to an "apparent disconnect" between the international figure and the 27-of-49 sample (para 27). Its own judgment gives that international figure as 1.9% in para 26 and 1.6% in para 27.

The court also noted that the NHS website called blockers "fully reversible" until June 2020 (paras 66–67). It quoted a 2019 Health Research Authority report that raised "concerns that the treatment might be responsible for generating persistence, rather than 'creating space to decide'" (para 52). For the wider evidence, see puberty blockers.

Procedural history

Outcome

What the High Court decided (1 December 2020)

The Divisional Court did not find the Tavistock's policy unlawful, and it rejected the claim that the information given to children was inadequate. It said the problem was "not the information given, but the ability of the children and young people, to understand and most importantly weigh up that information" (para 150). It held that, to be Gillick-competent, a child would need to understand eight matters. These included that "the vast majority of patients taking PBs go on to CSH" (cross-sex hormones), the impact on fertility and sexual function, and "the fact that the evidence base for this treatment is as yet highly uncertain" (para 138). Its central conclusion was:

It is highly unlikely that a child aged 13 or under would be competent to give consent to the administration of puberty blockers. It is doubtful that a child aged 14 or 15 could understand and weigh the long-term risks and consequences of the administration of puberty blockers. — (High Court 2020, para 151)

For 16- and 17-year-olds, who are presumed able to consent under section 8 of the Family Law Reform Act 1969, the court said clinicians "may well regard these as cases where the authorisation of the court should be sought" (para 152).

What the Court of Appeal decided (17 September 2021)

The Court of Appeal did not rule on whether blockers are safe or effective. It held that the Divisional Court, having found nothing unlawful, should simply have dismissed the claim. Instead it had made a declaration and given guidance that implied "factual findings that the Divisional Court was not equipped to make" (Court of Appeal 2021, para 65). The court reasoned that generalising about competence by age conflicted with Gillick itself:

the court was not in a position to generalise about the capability of persons of different ages to understand what is necessary for them to be competent to consent to the administration of puberty blockers. — (Court of Appeal 2021, para 85)

It held that under Gillick "it was for clinicians rather than the court to decide on competence" (para 87). It did, however, acknowledge "the difficulties and complexities" of the question. It warned that clinicians "will be alive to the possibility of regulatory or civil action where, in individual cases, the issue can be tested" (para 92), which leaves individual negligence claims open as a separate route (see detransitioner lawsuits).

The Tavistock "welcomed the decision" (Guardian 2021). Bell said she was disappointed and would seek to appeal to the Supreme Court (BBC 2021).

Current status (as of October 2026)

The litigation is over, and the Court of Appeal's judgment is the governing law on Gillick competence. In practice, though, policy has overtaken the question: puberty blockers for gender dysphoria are no longer routinely available to under-18s in the UK outside a clinical trial.

Significance

Aftermath: Cass Review, GIDS closure and restrictions

The case ran alongside the Cass Review, commissioned in 2020 (High Court 2020, para 97). After its interim report, NHS England announced on 28 July 2022 that GIDS would close; a review group had found a predominantly "affirmative, non-exploratory approach" (BMJ 2022). GIDS closed at the end of March 2024 (Tortoise 2024). Since then:

• March 2024: NHS England decided not to routinely commission puberty blockers for gender incongruence, after an evidence review by the National Institute for Health and Care Excellence (NICE) (DHSC 2024).
• 10 April 2024: the Cass Review's final report found "remarkably weak" evidence for puberty blockers and hormones in under-18s (Cass 2024; BBC 2024). See evidence reviews.
• 29 May 2024: emergency legislation restricted private and overseas prescribing. On 29 July 2024 the High Court rejected a challenge to it brought by TransActual with Good Law Project support (BBC, July 2024).
• 11 December 2024: Health Secretary Wes Streeting made the ban indefinite, with a review due in 2027 (BBC, December 2024).
• 2025–2026: the NHS-commissioned PATHWAYS trial of puberty blockers was paused in February 2026 and resumed with minimum ages and stronger safeguards. On 31 July 2026 the High Court refused a judicial review by campaigners seeking to stop it (BBC 2026; Clinical Trials Arena 2026).

Legal significance

• Gillick reaffirmed. Capacity is assessed child by child by clinicians, not by court-set age bands, and parents can consent where a child cannot (AB v CD).
• Judicial review is not a fact-finding forum. Contested clinical evidence cannot be resolved without cross-examination (Court of Appeal 2021, para 64). Individual negligence claims are a separate route. A proposed group action against the Tavistock was announced in 2022, but as of October 2026 no group litigation order (a court order letting many similar claims be managed together) has been reported.
• The record survives the reversal. The High Court's account of the Tavistock's data gaps (age, autism, progression) was not contradicted on appeal and is still cited in the informed-consent debate.

Reactions from both sides

On 1 December 2020 Bell said the judgment "will protect vulnerable young people" (statement reproduced by Safe Schools Alliance UK, a gender-critical campaign group). NHS England "welcomed the clarity". The trans-youth charity Mermaids called it "a devastating blow" and "a potential catastrophe for trans young people across the country" (BBC 2020). When the Supreme Court refused permission in 2022, trans-led groups that had intervened welcomed it, and PinkNews (an LGBT news outlet) described a "sigh of relief" (PinkNews 2022). Trans commenters online often argue that blockers spare young people the irreversible effects of puberty. One wrote that blockers "simply prevent the irreplaceable effects of the wrong puberty" (transbianbean, trans woman (MTF)). That view echoes the evidence of witnesses J and N.

What detransitioners say about the case

On r/detrans the case is widely seen as a turning point, and Bell as someone who took a public risk on others' behalf. One commenter, writing just after the High Court ruling, summarised her reading of it:

It's not an outright ban on transition for any and all children. It's just mandating that a neutral outsider be able to look in on each case of an under-16 child being started on a transition- and only because the clinic failed to take appropriate care. —Takeshold, detrans female

Others focused on Bell being visible at all:

I am so proud of Keira for her bravery. We don't yet have accurate statistics on how many detransitioners (especially FtMtF) there actually are and I'm sick of people pretending like we don't exist. —ConsciousDisaster183, desisted female

Views are not uniform. One moderator wrote that she did not think Bell was "the best voice to represent detrans people" but opposed "erasing and silencing her" (DetransIS, detrans female).

What detransitioners report about consent as teenagers

Some people who started treatment young describe, in hindsight, the problem the High Court identified:

My brain was not developed enough to fully comprehend the (sometimes irreversible) changes that HRT would bring, and if the therapists would have just tried to actually delve deeper they would have realized that what I mistook as gender dysphoria was actually just deeply rooted trauma and self-hatred. —Luzzenz, detrans female (blockers at 14, testosterone at 16)

I hold so much resentment towards my doctors, family and friends who let me do this to myself. I was 16 FFS! Now that im 22, it's so easy to see how immature 16 year olds are. —Aware-Resist-8655, detrans male

These are self-selected accounts and cannot show how common such regret is. The High Court itself noted that no reliable follow-up data existed (paras 57–59), and that gap is still a central theme of transition regret research. More first-hand accounts are in the video archive and the /stats pages.

Related pages

• Detransitioner lawsuits: cases, claims and outcomes
• Puberty blockers
• Evidence reviews (Cass Review and international reviews)
• Critique of the informed-consent model
• Fertility after medical transition
• Mastectomy
• Autism and gender dysphoria
• Gender exploratory therapy
• Support resources

References

• High Court of England and Wales (Divisional Court) (2020). R (Quincy Bell and A) v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274 (Admin), 1 December 2020. judgment (PDF), judiciary.uk page.
• Court of Appeal (Civil Division) (2021). Bell and another v Tavistock and Portman NHS Foundation Trust [2021] EWCA Civ 1363, 17 September 2021. judgment (PDF).
• Rook Irwin Sweeney (6 May 2022). Supreme Court rejects application for permission to appeal Bell v Tavistock (solicitors for interveners supporting the Tavistock). source.
• Daily Mail (May 2022). Landmark puberty-blockers ruling will NOT be challenged at Supreme Court. source.
• PinkNews (6 May 2022). Trans community breathes sigh of relief as Supreme Court rejects puberty blockers case (LGBT news outlet). source.
• Carmichael P, Butler G, Masic U, et al. (2021). Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLoS ONE 16(2): e0243894. source.
• Bell K (7 April 2021). Keira Bell: My Story. Persuasion. source.
• Safe Schools Alliance UK (gender-critical campaign group) (3 December 2020). Keira Bell statement on High Court ruling. source.
• BBC News (1 December 2020). Puberty blockers: Under-16s 'unlikely to be able to give informed consent'. source.
• BBC News (17 September 2021). Ruling limiting under-16s puberty blockers overturned. source.
• The Guardian (17 September 2021). Appeal court overturns UK puberty blockers ruling for under-16s. source.
• Dyer C (2022). NHS gender identity service to close and be replaced by regional centres. BMJ 378:o1916. source.
• Tortoise Media (2 April 2024). Tavistock: Britain's biggest gender identity clinic has closed. source.
• Cass H (2024). Independent review of gender identity services for children and young people: Final report. study page, source.
• BBC News (2024). Cass Review: Gender care report author attacks 'misinformation'. source.
• Department of Health and Social Care (11 December 2024). Puberty blockers: what you need to know. source.
• BBC News (29 July 2024). Puberty blockers ban is lawful, says High Court. source.
• BBC News (11 December 2024). Puberty blockers for under-18s banned indefinitely. source.
• BBC News (2026). Puberty blockers trial can start recruiting children after judge rejects legal challenge. source.
• Clinical Trials Arena (3 August 2026). High Court gives go-ahead for UK puberty blocker trial to continue. source.